Paclitaxel-induced pseudoscleroderma

Krzysztof Sadko; Anna Płaszczyńska; Justyna Czarny

doi:10.5114/dr.2022.123985

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2022
vol. 109

Send email

Copy url:

abstract:

Case report

Paclitaxel-induced pseudoscleroderma

Krzysztof G. Sadko

¹

,

Anna Płaszczyńska

²

,

Justyna Czarny

³

Dermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

Department and Clinic of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

Dermatol Rev/Przegl Dermatol 2022, 109, 299-309

DOI: https://doi.org/10.5114/dr.2022.123985

Online publish date: 2023/01/16

View full text Get citation

PlumX metrics:

Introduction
Pseudoscleroderma (scleroderma-like disease) is a group of rare and chronic skin conditions that mimics systemic sclerosis. The etiology of these diseases covers a wide range of causative factors, including drugs used in chemotherapy.

Case Report
A 78-year-old woman was admitted due to significant hardening of the skin in the dorsal surface of feet and distal part of the lower legs. These lesions occurred after a concluded chemotherapy with paclitaxel for right breast cancer. Treatment with pentoxifylline, topical clobetasol and 30% urea ointment was introduced. One month later an improvement in the clinical condition was observed.

Conclusions
We present a case of pseudoscleroderma caused by paclitaxel and successfully treated with pentoxifylline and topical clobetasole. Conclusion of the treatment course with paclitaxel may have positively influenced the outcome in this treatment.

keywords:

Paclitaxel-induced pseudoscleroderma

Krzysztof G. Sadko 1 , Anna Płaszczyńska 2 , Justyna Czarny 3

pseudosklerodermia, paklitaksel, chemioterapia

Krzysztof G. Sadko

¹

,

Anna Płaszczyńska

²

,

Justyna Czarny

³